BREAKING
Cavco Industries Jumps 7.1% Amid Sector-Wide Rally 3 days ago Materion Jumps 7.7% Amid Sector-Wide Selling 3 days ago Advanced Drainage Systems Jumps 7.7% Amid Sector-Wide Rally 3 days ago AeroVironment Drops 6.3% Amid Sector-Wide Selling 3 days ago WaFd Jumps 7.5% Amid Sector-Wide Selling 3 days ago Why Albemarle Is Dropping 9.0%? 3 days ago Chord Energy Drops 9.6% Amid Sector-Wide Selling 3 days ago Onto Innovation Jumps 7.9% After Evercore ISI Group Main to Outperform 3 days ago Occidental Petroleum Drops 7.5% Amid Sector-Wide Selling 3 days ago Why Netflix Is Dropping 9.8%: Barclays Main to Equal-Weight 3 days ago Cavco Industries Jumps 7.1% Amid Sector-Wide Rally 3 days ago Materion Jumps 7.7% Amid Sector-Wide Selling 3 days ago Advanced Drainage Systems Jumps 7.7% Amid Sector-Wide Rally 3 days ago AeroVironment Drops 6.3% Amid Sector-Wide Selling 3 days ago WaFd Jumps 7.5% Amid Sector-Wide Selling 3 days ago Why Albemarle Is Dropping 9.0%? 3 days ago Chord Energy Drops 9.6% Amid Sector-Wide Selling 3 days ago Onto Innovation Jumps 7.9% After Evercore ISI Group Main to Outperform 3 days ago Occidental Petroleum Drops 7.5% Amid Sector-Wide Selling 3 days ago Why Netflix Is Dropping 9.8%: Barclays Main to Equal-Weight 3 days ago
ADVERTISEMENT
Breaking News

Unicycive Therapeutics, Inc. (UNCY) Reports FY2025 Earnings

Unicycive Therapeutics, Inc. (UNCY) posted Q4 2025 basic and diluted EPS of -$1.67.

March 30, 2026 1 min read

Unicycive Therapeutics, Inc. (UNCY) posted Q4 2025 basic and diluted EPS of -$1.67.

UNCYUNCY|EPS -$1.67|Net Loss $26.6M

Unicycive Therapeutics, Inc. (UNCY) posted FY 2025 basic and diluted EPS of -$1.67.

Unicycive Therapeutics, Inc. is a Biotechnology company. Bottom line showed a net loss of $26.6M.

Wall Street consensus stands at 10 buy, 1 hold, 0 sell.

This article was generated with the assistance of AI technology and reviewed for accuracy. AlphaStreet may receive compensation from companies mentioned in this article. This content is for informational purposes only and should not be considered investment advice.

ADVERTISEMENT